etoricoxib + diacerein

etoricoxib + diacerein is a fixed-dose combination therapy developed by Laboratorios Liomont for the treatment of pain associated with osteoarthritis, specifically targeting knee and hip joints. Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that provides rapid analgesic and anti-inflammatory effects by reducing prostaglandin synthesis. Diacerein is an anthraquinone derivative that acts as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) by inhibiting interleukin-1 beta (IL-1β), a key pro-inflammatory cytokine involved in cartilage degradation and joint inflammation. This combination aims to provide both immediate symptomatic relief and potential long-term disease-modifying benefits in patients with osteoarthritis.

Brand names

Artrocox D

Other names

diacerein + etoricoxib